Loading...
Please wait, while we are loading the content...
Deprenyl decreases an endogenous parkinsonism-inducing compound, 1-benzyl-1,2,3,4-tetrahydroisoquinoline in mice: in vivo and in vitro studies
| Content Provider | Semantic Scholar |
|---|---|
| Author | Kotake, Yaichiro Tasaki, Yoshikazu Hirobe, Masaaki Ohta, Shigeru |
| Copyright Year | 1998 |
| Abstract | We examined the effect of deprenyl, a promising drug for the therapy of Parkinson's disease on the formation of a parkinsonism-inducing compound, 1-benzyl-1,2,3,4-tetrahydroisoquinoline (1BnTIQ). The 1BnTIQ content was significantly decreased in the brain of deprenyl-treated mouse in vivo, and deprenyl also inhibited 1BnTIQ formation from phenethylamine by a mouse brain homogenate supernatant in vitro. In vivo, the content of a parkinsonism-preventing compound, 1-methyl-1,2,3, 4-tetrahydroisoquinoline (1MeTIQ) was slightly increased in mice injected with deprenyl. The marked decrease of the ratio of 1BnTIQ to 1MeTIQ might play a role in the clinical effect of deprenyl. |
| Starting Page | 341 |
| Ending Page | 343 |
| Page Count | 3 |
| File Format | PDF HTM / HTML |
| DOI | 10.1016/S0006-8993(97)01560-6 |
| Alternate Webpage(s) | https://api.elsevier.com/content/article/pii/S0006899397015606 |
| Alternate Webpage(s) | https://www.sciencedirect.com/science/article/pii/S0006899397015606?dgcid=api_sd_search-api-endpoint |
| PubMed reference number | 9518683 |
| Alternate Webpage(s) | https://doi.org/10.1016/S0006-8993%2897%2901560-6 |
| Journal | Medline |
| Volume Number | 787 |
| Journal | Brain Research |
| Language | English |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Article |
